Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome
Launched by MAURO H. SCHENONE · Mar 27, 2024
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The condition occurs when part of the heart doesn't develop properly so the heart is not able to pump blood around the body effectively. Babies born with this condition require surgery and are often left with a lifelong heart disability. A number of babies with this condition will die during pregnancy or within the first year of life (approximately 10-40%). We are investigating a treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve. The aortic valve function is to allow easy flow from the heart to the body and prevent blood from returni...
Gender
FEMALE
Eligibility criteria
- • Inclusion Criteria
- • Pregnant women 18-45 years of age.
- • Gestational age between 21 0/7 and 29 6/7 weeks of gestation
- • The mother must be healthy enough to undergo surgery.
- • The individual being enrolled must be able to provide informed consent.
- • Dominant cardiac defect is valvar
- * Evolving hypoplastic left heart syndrome defined as depressed left ventricle systolic and at least one of the following:
- • Retrograde flow in the transverse aortic arch
- • Two of the following: (1) left to right flow across the atrial septum (bulging of the septum left to right in cases of intact atrial septum); (2) monophasic mitral valve inflow; (3) bidirectional flow in the pulmonary veins.
- * Potential for a technically successful and postnatal biventricular outcome defined as left ventricle long axis Z-score equal or greater than -2 PLUS at least 4 of the following 5 criteria:
- • Left ventricle long axis Z-score more than zero
- • Left ventricle short axis Z-score more than zero
- • Aortic annulus Z-score more than -3.5
- • Mitral valve annulus Z-score more than -2
- • Left ventricle generating a maximal instantaneous gradient (MIG) equal or greater than 20 mmHg (or by mitral regurgitation jet greater than or equal to 20 mmHg).
- • Exclusion Criteria
- • Patient is less than 18 years of age or more than 45 years of age.
- • Contraindication to anesthesia or surgery
- • Preterm labor or cervical length \<20 mm at enrollement or uterine anomaly strongly predisposing to preterm delivery.
- • Other fetal anomalies that significantly impact fetal/neonatal survival (e.g., congenital diaphragmatic hernia, bilateral renal agenesis, etc.)
- • Fetal aneuploidy and pathogenic findings on Karyotype or Microarray that impact significantly the fetal/neonatal survival.
- * Cases with all the following criteria:
- • Left ventricle pressure ≤ 47 mmHg
- • MV dimension Z-score \< 0.1
- • MV inflow time Z-score \< -2
About Mauro H. Schenone
Mauro H. Schenone is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient care through innovative study designs and rigorous methodologies. With a focus on developing effective therapeutic interventions, Schenone leverages extensive expertise in clinical operations and regulatory compliance to ensure the successful execution of trials. By fostering collaboration among multidisciplinary teams, he aims to facilitate the translation of scientific discoveries into clinical practice, ultimately improving health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Patients applied
Trial Officials
Mauro Schenone, MD
Principal Investigator
Mayo Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported